07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Qiagen, British Columbia Cancer Agency, Columbia University deal

Qiagen entered two exclusive license agreements for cancer biomarkers that the company plans to use to develop diagnostics. The company licensed worldwide rights from the university to fibroblast growth factor (FGF) receptor ( FGFR )-transforming...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

Takeda, British Columbia Cancer Agency deal

Takeda announced a research partnership with agency to discover and develop cancer targets based on gene analysis. The deal is the first for Takeda's new Shonan Incubation Laboratories program, under which the pharma invites distinguished...
01:04 , Aug 30, 2012 |  BC Extra  |  Company News

Takeda partners with cancer agency

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) announced a research partnership with the British Columbia Cancer Agency to discover and develop cancer targets based on gene analysis. The deal is the first for Takeda's new Shonan Incubation...
07:00 , May 7, 2012 |  BioCentury  |  Emerging Company Profile

Essa: A baby Cougar

Essa Pharma Inc. is developing a next-generation hormone antagonist that blocks a previously intractable androgen receptor domain, a strategy the company expects to work in advanced castration-resistant prostate cancer even after other androgen receptor blockers...
00:56 , Oct 20, 2011 |  BC Extra  |  Politics & Policy

Panel releases draft update to HPV screening recommendations

The U.S. Preventive Services Task Force (USPSTF) released a draft of new cervical cancer screening guidelines that partially clarifies recommendations on the use of high-risk HPV screening. The draft recommends against HPV screening in women...
07:00 , Mar 25, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Tumor-associated macrophages as a biomarker for therapy responsiveness and patient survival in Hodgkin's lymphoma A study in patient samples suggests that tumor-associated macrophages could be useful...
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma B cell lymphoma 2 (BCL-2; BCL2); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc) Comprehensive cytogenetic analysis of lymphoma patients could help identify patients who...
07:00 , May 7, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer N-cadherin; snail1; twist homolog (TWIST); vimentin (VIM); Y box-binding protein I (YB1) A mouse and cell-culture study suggests that...
07:00 , Apr 30, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Dihydrofolate reductase (DHFR); neuraminidase (NEU1; SIAL1) In vitro studies suggest that NSC89853 could be useful for treating...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models High-speed, parallel DNA sequence assembly A high-speed DNA sequence assembly algorithm, Assembly by Short Sequences (ABySS), could offer a quick and...